Tumor Infiltrating Lymphocytes and CD8+T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma
Tumor Infiltrating Lymphocytes and CD8+T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma
复制标题
DOI：
10.1007/s12105-019-01101-6
复制
发表时间：
2019-11-20
影响因子：
2.1
通讯作者：
Fountzilas, Georgios
中科院分区：
文献类型：
--
作者：
Chatzopoulos, Kyriakos;Kotoula, Vassiliki;Fountzilas, Georgios
为探讨肿瘤浸润淋巴细胞（TIL）和CD 8 + T细胞亚群在喉鳞状细胞癌（LSCC）患者中的预后意义，对283例LSCC患者进行了检测。在整个切片上对TIL密度进行形态学评估。在每个肿瘤的多个组织微阵列核心上评估CD 8+细胞计数/mm（2）（高/低CD 8 +/mm（2）的中位数计数）。TIL密度和CD 8+计数彼此弱相关（斯皮尔曼rho = 0.348）。在28%的肿瘤中显示出异质性CD 8+计数/mm 2。在单变量分析中，观察到CD 8表达和淋巴结状态之间的显著相互作用;在淋巴结阳性患者中，与低CD 8+肿瘤患者相比，高CD 8+肿瘤患者复发风险降低77%（相互作用p < 0.001），死亡风险降低74%（相互作用p = 0.002）。在多变量分析中，较高的TIL密度独立地赋予整个队列中较低的复发风险（HR 0.87; 95% CI 0.77-0.98; Wald's p = 0.017）和淋巴结阳性患者（HR 0.41; 95% CI 0.23-0.75; p = 0.003），死亡（分别为p = 0.025和p = 0.003）。在任何分析背景下，高CD 8+均不是显著的独立预后标志物。与形态学评估的TIL密度相比，CD 8+浸润的评估似乎不能提供额外的预后信息。也似乎较高的TIL密度和CD 8+浸润的有利预后影响主要涉及淋巴结阳性而不是淋巴结阴性疾病。如果在较大的淋巴结阳性队列中得到验证，这些发现值得考虑用于喉鳞状细胞癌免疫细胞浸润的诊断发展。
To evaluate the prognostic significance of tumor infiltrating lymphocytes (TILs) and of CD8+ T-cell subsets in patients with surgically treated laryngeal squamous cell carcinoma (LSCC), LSCC from 283 patients were examined. TIL density was morphologically assessed on whole sections. CD8+ cell counts/mm(2) were evaluated on multiple tissue microarray cores per tumor (median counts for high/low CD8+/mm(2)). TIL density and CD8+ counts weakly correlated with each other (Spearman's rho = 0.348). Heterogeneous CD8+ counts/mm(2) were demonstrated in 28% of the tumors. In univariate analysis, a significant interaction was observed between CD8 expression and nodal status with respect to outcome; in node-positive patients, those with high CD8+ tumors had 77% lower risk of relapse (interaction p < 0.001) and 74% lower risk for death (interaction p = 0.002) compared to patients with low CD8+ tumors. In multivariate analysis, higher TIL density independently conferred lower risk for relapse in the entire cohort (HR 0.87; 95% CI 0.77-0.98; Wald's p = 0.017) and in node-positive patients (HR 0.41; 95% CI 0.23-0.75; p = 0.003) and, similarly, for death (p = 0.025 and p = 0.003, respectively). High CD8+ was not a significant independent prognostic marker in any analysis setting. The assessment of CD8+ infiltrates does not seem to offer additional prognostic information over the morphologically assessed TIL density. It also appears that the favorable prognostic impact of higher TIL density and CD8+ infiltrates mostly concerns node-positive but not node-negative disease. If validated in larger node-positive cohorts, these findings are worth considering for the diagnostic development of immune cell infiltrates in LSCC.